Label: MUPIROCIN CALCIUM- mupirocin calcium cream

  • NDC Code(s): 66993-942-15, 66993-942-31
  • Packager: Prasco Laboratories
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application Authorized Generic

Drug Label Information

Updated 09/14

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Mupirocin Calcium Cream, 2% contains the dihydrate crystalline calcium hemi-salt of the antibiotic mupirocin. Chemically, it is (αE,2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-β-methyl-2H-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid, calcium salt (2:1), dihydrate.

    The molecular formula of mupirocin calcium is (C26H43O9)2Ca•2H2O, and the molecular weight is 1075.3. The molecular weight of mupirocin free acid is 500.6. The structural formula of mupirocin calcium is:

    Structural Formula of mupirocin calcium

    Mupirocin Calcium Cream, 2% is a white cream that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% mupirocin free acid) in an oil and water-based emulsion. The inactive ingredients are benzyl alcohol, cetomacrogol 1000, cetyl alcohol, mineral oil, phenoxyethanol, purified water, stearyl alcohol, and xanthan gum.

    Close
  • CLINICAL PHARMACOLOGY

    Pharmacokinetics:

    Systemic absorption of mupirocin through intact human skin is minimal. The systemic absorption of mupirocin was studied following application of Mupirocin Calcium Cream, 2% 3 times daily for 5 days to various skin lesions (>10 cm in length or 100 cm2 in area) in 16 adults (aged 29 to 60 years) and 10 children (aged 3 to 12 years). Some systemic absorption was observed as evidenced by the detection of the metabolite, monic acid, in urine. Data from this trial indicated more frequent occurrence of percutaneous absorption in children (90% of subjects) compared with adults (44% of subjects); however, the observed urinary concentrations in children (0.07 to 1.3 mcg/mL [1 pediatric subject had no detectable level]) are within the observed range (0.08 to 10.03 mcg/mL [9 adults had no detectable level]) in the adult population. In general, the degree of percutaneous absorption following multiple dosing appears to be minimal in adults and children. Any mupirocin reaching the systemic circulation is rapidly metabolized, predominantly to inactive monic acid, which is eliminated by renal excretion.

    Microbiology:

    Mupirocin is an antibacterial agent produced by fermentation using the organism Pseudomonas fluorescens. It is active against a wide range of gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). It is also active against certain gram-negative bacteria. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase. Due to this unique mode of action, mupirocin demonstrates no in vitro cross-resistance with other classes of antimicrobial agents.

    Resistance occurs rarely; however, when mupirocin resistance does occur, it appears to result from the production of a modified isoleucyl-tRNA synthetase. High-level plasmid-mediated resistance (MIC >1,024 mcg/mL) has been reported in some strains of Staphylococcus aureus and coagulase-negative staphylococci.

    Mupirocin is bactericidal at concentrations achieved by topical application. The minimum bactericidal concentration (MBC) against relevant pathogens is generally 8-fold to 30-fold higher than the minimum inhibitory concentration (MIC). In addition, mupirocin is highly protein bound (>97%), and the effect of wound secretions on the MICs of mupirocin has not been determined.

    Mupirocin has been shown to be active against most strains of S. aureus and Streptococcus pyogenes, both in vitro and in clinical trials (see INDICATIONS AND USAGE). The following in vitro data are available, BUT THEIR CLINICAL SIGNIFICANCE IS UNKNOWN. Mupirocin is active against most strains of Staphylococcus epidermidis and Staphylococcus saprophyticus.

    Close
  • INDICATIONS AND USAGE

    Mupirocin Calcium Cream, 2% is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible strains of S. aureus and S. pyogenes.

    Close
  • CONTRAINDICATIONS

    Mupirocin Calcium Cream, 2% is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

    Close
  • WARNINGS

    Avoid contact with the eyes. In case of accidental contact, rinse well with water.

    In the event of a sensitization or severe local irritation from Mupirocin Calcium Cream, 2%, usage should be discontinued, and appropriate alternative therapy for the infection instituted.

    Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including mupirocin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

    C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

    If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

    Close
  • PRECAUTIONS

    General:

    As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi (see DOSAGE AND ADMINISTRATION).

    Mupirocin Calcium Cream, 2% is not formulated for use on mucosal surfaces.

    Information for Patients:

    Use this medication only as directed by the healthcare provider. It is for external use only. Avoid contact with the eyes. If Mupirocin Calcium Cream, 2% gets in or near the eyes, rinse thoroughly with water.
    The treated area may be covered by gauze dressing if desired.
    Report to the healthcare provider any signs of local adverse reactions. The medication should be stopped and the healthcare provider contacted if irritation, severe itching, or rash occurs.
    If no improvement is seen in 3 to 5 days, contact the healthcare provider.

    Drug Interactions:

    The effect of the concurrent application of topical mupirocin calcium cream and other topical products has not been studied.

    Carcinogenesis, Mutagenesis, Impairment of Fertility:

    Long-term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted.

    Results of the following studies performed with mupirocin calcium or mupirocin sodium in vitro and in vivo did not indicate a potential for mutagenicity: Rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, Salmonella reversion test (Ames), Escherichia coli mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice.

    Fertility studies were performed in rats with mupirocin administered subcutaneously at doses up to 49 times a human topical dose of 1 gram/day (approximately 20 mg mupirocin per day) on a mg/m2 basis and revealed no evidence of impaired fertility from mupirocin sodium.

    Pregnancy:

    Teratogenic Effects:

    Pregnancy Category B. Teratology studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 78 and 154 times, respectively, a human topical dose of 1 gram/day (approximately 20 mg mupirocin per day) on a mg/m2 basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

    Nursing Mothers:

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Mupirocin Calcium Cream, 2% is administered to a nursing woman.

    Pediatric Use:

    The safety and effectiveness of Mupirocin Calcium Cream, 2% have been established in the age groups 3 months to 16 years. Use of Mupirocin Calcium Cream, 2% in these age groups is supported by evidence from adequate and well-controlled trials of mupirocin calcium cream in adults with additional data from 93 pediatric subjects studied as part of the pivotal trials in adults (see CLINICAL STUDIES).

    Geriatric Use:

    In 2 well-controlled trials, 30 subjects older than 65 years were treated with mupirocin calcium cream. No overall difference in the efficacy or safety of mupirocin calcium cream was observed in this patient population when compared with that observed in younger patients.

    Close
  • ADVERSE REACTIONS

    In 2 randomized, double-blind, double-dummy trials, 339 subjects were treated with topical mupirocin calcium cream plus oral placebo. Adverse events thought to be possibly or probably drug-related occurred in 28 (8.3%) subjects. The incidence of those events that were reported in at least 1% of subjects enrolled in these trials were: headache (1.7%), rash, and nausea (1.1% each).

    Other adverse events thought to be possibly or probably drug-related which occurred in less than 1% of subjects were: abdominal pain, burning at application site, cellulitis, dermatitis, dizziness, pruritus, secondary wound infection, and ulcerative stomatitis.

    In a supportive study in the treatment of secondarily infected eczema, 82 subjects were treated with Mupirocin Calcium Cream, 2%. The incidence of adverse events thought to be possibly or probably drug-related was as follows: nausea (4.9%), headache, and burning at application site (3.6% each), pruritus (2.4%) and 1 report each of abdominal pain, bleeding secondary to eczema, pain secondary to eczema, hives, dry skin, and rash.

    Systemic allergic reactions, including anaphylaxis, urticaria, angioedema, and generalized rash have been reported in patients treated with formulations of mupirocin.

    Close
  • OVERDOSAGE

    Intravenous infusions of 252 mg, as well as single oral doses of 500 mg of mupirocin, have been well tolerated in healthy adult subjects. There is no information regarding overdose of Mupirocin Calcium Cream, 2%.

    Close
  • DOSAGE AND ADMINISTRATION

    A small amount of Mupirocin Calcium Cream, 2% should be applied to the affected area 3 times daily for 10 days. The area treated may be covered with gauze dressing if desired. Patients not showing a clinical response within 3 to 5 days should be re-evaluated.

    Close
  • CLINICAL STUDIES

    The efficacy of topical mupirocin calcium cream for the treatment of secondarily infected traumatic skin lesions (e.g., lacerations, sutured wounds, and abrasions not more than 10 cm in length or 100 cm2 in total area) was compared with that of oral cephalexin in 2 randomized, double-blind, double-dummy clinical trials. Clinical efficacy rates at follow-up in the per-protocol populations (adults and pediatric subjects included) were 96.1% for mupirocin calcium cream (n = 231) and 93.1% for oral cephalexin (n = 219). Pathogen eradication rates at follow-up in the per-protocol populations were 100% for both mupirocin calcium cream and oral cephalexin.

    Pediatrics:

    There were 93 pediatric subjects aged 2 weeks to 16 years enrolled per protocol in the secondarily infected skin lesion trials, although only 3 were less than 2 years of age in the population treated with mupirocin calcium cream. Subjects were randomized to either 10 days of topical mupirocin calcium cream 3 times daily or 10 days of oral cephalexin (250 mg 4 times daily for subjects >40 kg or 25 mg/kg/day oral suspension in 4 divided doses for subjects ≤40 kg). Clinical efficacy at follow-up (7 to 12 days post-therapy) in the per-protocol populations was 97.7% (43/44) for mupirocin calcium cream and 93.9% (46/49) for cephalexin. Only 1 adverse event (headache) was thought to be possibly or probably related to drug therapy with mupirocin calcium cream in the intent-to-treat pediatric population of 70 children (1.4%).

    Close
  • HOW SUPPLIED

    Mupirocin Calcium Cream, 2% is supplied in 15-gram and 30-gram tubes.

    NDC 66993-942-15 (15-gram tube)

    NDC 66993-942-31 (30-gram tube)

    Store at or below 25°C (77°F). Do not freeze.

    Manufactured for:

    Prasco Laboratories

    Mason, OH 45040

    September 2014

    MUC-PS:3PI

    Close
  • PRINCIPAL DISPLAY PANEL

    PRINCIPAL DISPLAY PANEL

    NDC 66993-942-15

    Mupirocin Calcium Cream, 2%

    PRASCO

    15 grams (Net Wt.)

    Rx only

    Made in England

    10000000092136 Rev. 3/11

    Mupirocin Calcium Cream Prasco 15g carton
    Close
  • INGREDIENTS AND APPEARANCE
    MUPIROCIN CALCIUM 
    mupirocin calcium cream
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:66993-942
    Route of Administration TOPICAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    MUPIROCIN CALCIUM (MUPIROCIN) MUPIROCIN 20 mg  in 1 g
    Inactive Ingredients
    Ingredient Name Strength
    BENZYL ALCOHOL  
    CETETH-20  
    CETYL ALCOHOL  
    MINERAL OIL  
    PHENOXYETHANOL  
    WATER  
    STEARYL ALCOHOL  
    XANTHAN GUM  
    Product Characteristics
    Color WHITE Score     
    Shape Size
    Flavor Imprint Code
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:66993-942-15 1 in 1 CARTON 01/28/2013
    1 15 g in 1 TUBE; Combination Product Type = C112160
    2 NDC:66993-942-31 1 in 1 CARTON 01/28/2013
    2 30 g in 1 TUBE; Combination Product Type = C112160
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA authorized generic NDA050746 01/28/2013
    Labeler - Prasco Laboratories (065969375)
    Registrant - GlaxoSmithKline LLC (167380711)
    Close